Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer’s disease: a Bayesian meta-analysis Aim: The use of amyloid-beta (Aβ) clearance to support regulatory approvals of drugs in Alzheimer’s disease (AD) remains controversial. We evaluate Aβ as a potential trial-level surrogate endpoint for...

📢New article alert

New Research Article on “Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer’s disease: a Bayesian meta-analysis”.

🔗 becarispublishing.com/doi/10.57264...

#OpenAccess #JCER #AlzheimersDisease #MetaAnalysis #SurrogateEndpoints

International collaboration provides new guidance on the use of surrogate endpoints in cost-effectiveness analysis

#surrogateendpoints #costeffectivenessanalysis #NICERecommendations #healthtechnologyassessment #HTAs #HTAagencies #healthtechnologyassessmentdecisions #HTAdecisions #healtheconomicmodels #drugs #medicaldevices #HTAmanuals #CDAAMC #ICER #ZIN #IETS #RubixHealth
www.nice.org.uk/news/article...

2024 saw extensions to the SPIRIT and CONSORT reporting guidelines for reporting trials with surrogate endpoints

www.bmj.com/content/386/... (CONSORT-SURROGATE)

www.bmj.com/content/386/... (SPIRIT-SURROGATE)

#statsSky #reporting #clinicaltrials #surrogateendpoints #transparency #

@EraEdtaRegistry Kitty Jagar outlines some of the problems with running
RCTs in #nephrology #longtime #surrogateendpoints need to predict the clinical endpoint👆🏻 #eraedta19 @ERAEDTA @ynptweets @fjcaskey

Esp. noteworthy - attention drawn to assumptions that #SurrogateEndpoints used for approval are predictive of clinical outcomes.